Alector (ALEC) Competitors $3.07 -0.11 (-3.46%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$3.16 +0.09 (+2.90%) As of 10/7/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. AMPH, ZYME, EVO, TRML, CVAC, LENZ, CALT, ELVN, MAZE, and DNTHShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Amphastar Pharmaceuticals (AMPH), Zymeworks (ZYME), Evotec (EVO), Tourmaline Bio (TRML), CureVac (CVAC), LENZ Therapeutics (LENZ), Calliditas Therapeutics AB (publ) (CALT), Enliven Therapeutics (ELVN), Maze Therapeutics (MAZE), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Amphastar Pharmaceuticals Zymeworks Evotec Tourmaline Bio CureVac LENZ Therapeutics Calliditas Therapeutics AB (publ) Enliven Therapeutics Maze Therapeutics Dianthus Therapeutics Amphastar Pharmaceuticals (NASDAQ:AMPH) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Do insiders & institutionals hold more shares of AMPH or ALEC? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 9.7% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer AMPH or ALEC? Amphastar Pharmaceuticals currently has a consensus target price of $31.60, suggesting a potential upside of 22.34%. Alector has a consensus target price of $4.17, suggesting a potential upside of 35.72%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Alector 3 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13 Which has better valuation and earnings, AMPH or ALEC? Amphastar Pharmaceuticals has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$731.97M1.64$159.52M$2.679.67Alector$100.56M3.09-$119.05M-$1.16-2.65 Does the media favor AMPH or ALEC? In the previous week, Alector had 3 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for Alector and 4 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.66 beat Alector's score of 0.04 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AMPH or ALEC more profitable? Amphastar Pharmaceuticals has a net margin of 18.64% compared to Alector's net margin of -142.10%. Amphastar Pharmaceuticals' return on equity of 20.76% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals18.64% 20.76% 9.68% Alector -142.10%-112.06%-26.37% Which has more volatility and risk, AMPH or ALEC? Amphastar Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. SummaryAmphastar Pharmaceuticals beats Alector on 10 of the 16 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$321.86M$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.70%4.75%P/E Ratio-2.6521.4185.6026.85Price / Sales3.09466.25612.81135.13Price / CashN/A47.6737.7861.77Price / Book2.3810.0613.256.70Net Income-$119.05M-$52.22M$3.30B$276.44M7 Day Performance2.33%4.25%3.87%2.48%1 Month Performance11.23%12.50%8.33%8.79%1 Year Performance-33.69%26.68%88.97%34.41% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.7346 of 5 stars$3.07-3.5%$4.17+35.7%-32.1%$321.86M$100.56M-2.65270AMPHAmphastar Pharmaceuticals4.5247 of 5 stars$26.85+1.9%$31.60+17.7%-44.8%$1.25B$731.97M10.062,028Positive NewsZYMEZymeworks0.0129 of 5 stars$16.60+2.7%N/AN/A$1.25B$76.30M-17.11460EVOEvotec1.6366 of 5 stars$3.48-1.7%$5.40+55.2%+17.4%$1.24B$862.40M0.004,827TRMLTourmaline Bio1.6867 of 5 stars$47.74+0.0%$45.65-4.4%+79.6%$1.23BN/A-13.9244Short Interest ↓High Trading VolumeCVACCureVac4.0097 of 5 stars$5.37+0.4%$6.83+27.3%+82.2%$1.20B$579.18M5.59880LENZLENZ Therapeutics0.6848 of 5 stars$42.03+5.0%$49.60+18.0%+95.7%$1.20BN/A-22.12110CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ELVNEnliven Therapeutics2.5093 of 5 stars$20.01+7.8%$41.20+105.9%-26.7%$1.19BN/A-10.0150MAZEMaze Therapeutics3.9616 of 5 stars$27.00+2.5%$32.67+21.0%N/A$1.18B$167.50M0.00121High Trading VolumeDNTHDianthus Therapeutics3.1921 of 5 stars$36.71+2.4%$61.57+67.7%+31.0%$1.18B$6.24M-11.3080High Trading Volume Related Companies and Tools Related Companies Amphastar Pharmaceuticals Alternatives Zymeworks Alternatives Evotec Alternatives Tourmaline Bio Alternatives CureVac Alternatives LENZ Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Enliven Therapeutics Alternatives Maze Therapeutics Alternatives Dianthus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
